CA Patent

CA2027937A1 — Substituted 5-¬ (tetrazolyl)alkenyl|imidazoles

Assigned to SmithKline Beecham Corp · Expires 1991-04-26 · 35y expired

What this patent protects

ABSTRACT OF THE DISCLOSURE SUBSTITUTED 5-[(TETRAZOLYL)ALKENYL]IMIDAZOLES Angiotensin II receptor antagonists having the formula: which are useful in regulating hypertension and in the treatment of congestive heart failure, renal failure, and gla…

USPTO Abstract

ABSTRACT OF THE DISCLOSURE SUBSTITUTED 5-[(TETRAZOLYL)ALKENYL]IMIDAZOLES Angiotensin II receptor antagonists having the formula: which are useful in regulating hypertension and in the treatment of congestive heart failure, renal failure, and glaucoma, pharmaceutical compositions including these antagonists, and methods of using these compounds to produce angiotensin II receptor antagonism in mammals.

Drugs covered by this patent

Patent Metadata

Patent number
CA2027937A1
Jurisdiction
CA
Classification
—
Expires
1991-04-26
Drug substance claim
No
Drug product claim
No
Assignee
SmithKline Beecham Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.